Orthofix Medical (NASDAQ:OFIX) Releases Quarterly Earnings Results, Beats Estimates By $0.11 EPS

Orthofix Medical (NASDAQ:OFIX) issued its earnings results on Monday. The medical device company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.11, Zacks reports. Orthofix Medical had a negative return on equity of 14.05% and a negative net margin of 7.41%. The business had revenue of $207.86 million during the quarter, compared to analysts’ expectations of $210.52 million.

Here are the key takeaways from Orthofix Medical’s conference call:

• Third-quarter results were below expectations: U.S. spine fixation sales fell 5%, affected by market softness, supplier delays and instrument-set constraints. Orthofix lowered its 2026 outlook to $825–$830 million in net sales and $86–$88 million in adjusted EBITDA.
• Results were stronger in other businesses: Limb Reconstruction sales rose 9% and Therapeutic Solutions sales increased 4%; U.S. biologics was roughly flat sequentially, and management said it returned to year-over-year growth in October. Adjusted EBITDA rose to $26 million from $24.6 million a year earlier, despite lower spine revenue.
• Management is concentrating spine resources on core distributors, which generate about 80% of U.S. spinal implant revenue, and said supplier fixes are underway. It expects the VIRATA open-procedure system to launch in the fourth quarter and views the business as better positioned for 2027, though the recovery is expected to take time.
• Orthofix expects an approximately $22 million spine sales headwind in 2027 from European MDR requirements. A European distributor arrangement is expected to add about $15 million to 2026 sales, mostly in Q4, but creates a temporary cash-timing headwind because related cash receipts are expected in 2027.

Orthofix Medical Trading Up 0.4%

Shares of NASDAQ:OFIX opened at $7.90 on Tuesday. The firm has a fifty day moving average of $9.25 and a two-hundred day moving average of $10.96. The company has a quick ratio of 1.67, a current ratio of 2.84 and a debt-to-equity ratio of 0.55. Orthofix Medical has a 12-month low of $6.52 and a 12-month high of $16.42. The firm has a market capitalization of $321.77 million, a P/E ratio of -5.13 and a beta of 0.66.

More Orthofix Medical News

Here are the key news stories impacting Orthofix Medical this week:

• Positive Sentiment: Orthofix reported third-quarter adjusted earnings of $0.18 per share, above the $0.11 consensus estimate. Its reported GAAP loss per share also was narrower than analysts expected. Orthofix Q3 earnings estimates
• Negative Sentiment: The company forecast 2026 net sales of $825 million–$830 million, below the roughly $851 million analyst consensus. That outlook cut may signal softer growth expectations; Q3 revenue of $207.86 million also fell short of the $210.52 million estimate. Orthofix 2026 sales outlook
• Negative Sentiment: A report flagged FDA reclassification of bone growth stimulators as a competitive risk for Orthofix, potentially threatening its market position and margins if the regulatory change increases competition. FDA reclassification risk report

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on OFIX. Weiss Ratings lowered shares of Orthofix Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, November 3rd. Canaccord Genuity Group lowered their target price on Orthofix Medical from $18.00 to $13.00 and set a “buy” rating for the company in a research note on Monday, August 10th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $14.75.

About Orthofix Medical

Orthofix Medical Inc is a medical device company focused on spinal and orthopedic solutions. The company develops, manufactures and distributes products designed to help treat spinal disorders, support bone healing and address orthopedic trauma and related musculoskeletal conditions.

Its product portfolio includes spinal fixation and interbody systems, biologics and bone-grafting products, bone growth stimulation devices, and technologies for spinal motion preservation and deformity correction.